Semaglutide (injectable) vs Tirzepatide
Both are authorised incretin-based medicines with large human datasets; compare mechanism, indication, trial populations, outcomes, tolerability and current product status rather than declaring a universal winner.
| Attribute | Semaglutide (injectable) | Tirzepatide |
|---|---|---|
| Human evidence | Extensive Phase III evidence supports weight loss with regulated semaglutide. SELECT demonstrated cardiovascular benefit in a defined population, and STEP 9 showed improved knee-OA pain/function in adults with obesity. | Large Phase III obesity evidence shows substantial weight loss. SURMOUNT-OSA additionally demonstrated large reductions in sleep-apnea severity in adults with obesity and moderate-to-severe OSA. |
| Research focus | Obesity, weight management, cardiovascular outcomes, heart failure, osteoarthritis, type 2 diabetes | Type 2 diabetes, obesity, weight management |
| Regulatory status | Wegovy (semaglutide) is authorised in the EU for weight management in defined adults and adolescents; authorisation and dosing are product-, route-, indication- and jurisdiction-specific. | Tirzepatide is authorised in licensed products such as Mounjaro for type 2 diabetes and adult weight management in the EU; authorization is product- and jurisdiction-specific. |
| Route / formulation | Evidence for licensed pre-filled injection pens cannot establish identity, concentration, sterility or equivalence of unverified semaglutide vials or non-authorised products. | Unverified research-market material or non-authorised pens are not equivalent to licensed tirzepatide medicines merely because the active-ingredient name matches. |
Why these are compared
These compounds appear in the weight & body composition evidence landscape, but they are not interchangeable. Semaglutide (injectable) is long-acting glp-1 receptor agonist peptide analogue studied in obesity, weight management, cardiovascular outcomes, heart failure, osteoarthritis, type 2 diabetes; Tirzepatide is gip/glp-1 receptor agonist peptide studied in type 2 diabetes, obesity, weight management. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Semaglutide (injectable): Approved medicine — extensive multi-outcome evidence, formulation/indication specific.
Tirzepatide: Strong Phase III / approved-product evidence across multiple indication-specific outcomes.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
Direct head-to-head obesity trial evidence exists in development literature; page must use matched doses/populations and current authorised labels. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.